Get started
Work

LentiGlobin Administration to Sickle Cell Disease Patients: Effect on Serum Markers and Vaso-Occlusive Crisis

Year: 2024
Type: article
Abstract: LentiGlobin, an innovative gene therapy, introduces a modified beta-globin gene that yields an anti-sickling hemoglobin variant. It boosts total hemoglobin levels, mitigates hemolysis, curtails inflammation, and addresses iron overload by reducing transfusion requirements. These changes, in turn, provide insights into disease mechanisms and treatment outcomes. Alterations in serum markers, such as hemoglobin levels and inflammatory biomarkers, can illuminate the therapeutic effectiveness of LentiGlobin and its impact on mitigating complications such as vaso-occlusive crises. Therefore, the purpose of this narrative review is to discuss the effects of LentiGlobin administration on diverse serum biomarkers and its correlation with vaso-occlusive crises in individuals with sickle cell disease (SCD).
Source: Cureus
DOI: 10.7759/cureus.51881
Authors: Harendra Kumar, Vagisha Sharma, Sohmika S Wadhwa, Diksha Mahadeva Gowda, Sharanya Kaushik, Andrew M Joseph, Monica Karas, Jonathan Quinonez, Anthony Furiato
Institutions: Government Medical College, Kempegowda Institute of Medical Sciences, Vardhman Mahavir Medical College & Safdarjung Hospital, Nova Southeastern University, Palm Springs General Hospital, Dow University of Health Sciences, Bangalore Medical College and Research Institute
Language: English
Field: Medicine
Open Access status: diamond
OpenAlex ID: W4390660244
FWCI: 1.453
Cites: 20
Cited by: 4
Related to: 10